Subgroup analysis based on cytogenetic risk in patients with relapsed or refractory multiple myeloma in the CANDOR study

Ola Landgren, Katja Weisel, Laura Rosinol, Cyrille Touzeau, Mehmet Turgut, Roman Hajek, Peter Mollee, Jin Seok Kim, Natalie Shu, Xuguang Hu, Chuang Li, Saad Z. Usmani

Research output: Contribution to journalArticlepeer-review

4 Citations (Scopus)

Abstract

CANDOR compared the safety/efficacy of carfilzomib with dexamethasone and daratumumab (KdD) to carfilzomib with dexamethasone (Kd) in adults with relapsed/refractory multiple myeloma (RRMM). This CANDOR subgroup analysis evaluated outcomes based on cytogenetic risk. Overall response rates (KdD vs. Kd) were 81% versus 56% in high-risk and 87% versus 79% in standard-risk groups. Median progression-free survival was 11.2 versus 7.4 months in high-risk (hazard ratio, 0.56 [95% CI, 0.34, 0.93]) and not reached versus 16.6 months in standard-risk groups (0.56 [95% CI, 0.39, 0.80]). These data support the efficacy of KdD in RRMM treatment, including in patients with high-risk cytogenetics.

Original languageEnglish
Pages (from-to)988-993
Number of pages6
JournalBritish Journal of Haematology
Volume198
Issue number6
DOIs
Publication statusPublished - 2022 Sept

Bibliographical note

Publisher Copyright:
© 2022 British Society for Haematology and John Wiley & Sons Ltd.

All Science Journal Classification (ASJC) codes

  • Hematology

Fingerprint

Dive into the research topics of 'Subgroup analysis based on cytogenetic risk in patients with relapsed or refractory multiple myeloma in the CANDOR study'. Together they form a unique fingerprint.

Cite this